跳至主要内容
临床试验/NCT07029997
NCT07029997招募中不适用

Post-Market Clinical Follow-Up Study of the Solo+ Tympanostomy Tube Device

AventaMed DAC1 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2026年5月21日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
AventaMed DAC
入组人数
160
试验地点
1
主要终点
Procedure Success (Performance)

研究概览

简要总结

The purpose of this project is to collect information from the doctor notes about the use of the device, to monitor the tubes after surgery, and collect information from patients and parents/guardians about their views on the procedure. Since the device became available in Europe, it is important to collect information from both patients planned for the procedure (prospective) and those who already underwent the procedure (retrospective) to have collect as much data as possible.

详细描述

Patients are being asked to participate in this study because they have been treated, will be treated, or have undergone a treatment attempt with the Solo+ Tympanostomy Tube Device (Solo+ TTD), manufactured by AventaMed. The Solo+ TTD device is a CE marked device designed to deploy ear tubes across the ear drum.

Ear tubes (also known as tympanostomy tubes or ventilation tubes) are predominantly used in treating repeated or long-term middle ear infections, or to treat a build-up of fluid in the middle ear, mostly in children, yet also used for adults. Ear tube insertion allows for air to ventilate the middle ear space and drain fluid from the middle ear.

The Solo+ Tympanostomy Tube Device (Solo+ TTD) is an all-in-one device for the insertion of ear tubes using as little as topical anaesthesia, without requiring general anaesthesia as is the case for other similar devices. The Solo+ TTD is approved for use in children and adults. It is available in Europe and already in use by some clinics and hospitals.

The purpose of this study is to collect information about the use the Solo+ TTD.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
6 Months 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Subject and/or Parent/Guardian is able to understand the information document and (depending in the country's legislation) does not object participating or is willing to provide documented informed consent
  • •Subject was or will be treated, or had a treatment attempted with the study device.

排除标准

  • 未提供

研究组 & 干预措施

adults and pedriatic patients who have had eartubes inserted, both prospective and retrospective.

干预措施: Solo+ Tympanostomy Tube Device (Solo+ TTD) (Device)

结局指标

主要结局

Procedure Success (Performance)

时间窗: 48 months

Percentage of subjects in which the tympanostomy tube is inserted in all indicated ears in a single procedure without the need to schedule a secondary procedure

Functioning Tubes (Performance)

时间窗: 48 months

Percentage of ears with a functioning tube (without extrusion and without occlusion) at standard of care follow-up visits until tube extrusion or discharge from standard clinical care

Early Adverse Event (AE) Rates (Safety)

时间窗: 48 months

Incidence and nature of device- or procedure-related AEs (per ear and per subject) from the day of the procedure to first follow-up visit post procedure

次要结局

未报告次要终点

研究者

发起方
AventaMed DAC
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验